Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

355 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

NCT01231607

Androgenetic Alopecia

COMPLETED PHASE3

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

NCT01703520

Male Breast Cancer

COMPLETED

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

NCT00648791

Healthy

COMPLETED PHASE1

Treatment of Androgenetic Alopecia in Men for 24 Weeks

NCT04721548

Alopecia

COMPLETED PHASE3

Finasteride Treatment of Severe Nodulocystic Acne

NCT02502669

NODULOCYSTIC ACNE

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0906, finasteride / Duration of Treatment : 48 Weeks

Intervention Type DRUG

Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men 40 to 60 years of age, and in good general physical and mental health, with androgenetic alopecia

Exclusion Criteria

* History of previous bladder surgery, acute urinary retention, urethral strictures, repeated urethral catheterizations, repeated urinary tract infections, or active urinary tract infections
* History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any component of finasteride.

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No